-
RBM-007 was well-tolerated with no dose-limiting toxicities, no
systemic or ocular serious adverse events. -
Seven out of nine subjects showed evidence of RBM-007 bioactivity, in
terms of any vision gain or ≥50 µm improvement in central retinal
thickness after a single dose of RBM-007.
TOKYO–(BUSINESS WIRE)–RIBOMIC, Inc., a clinical stage pharmaceutical company specializing in
aptamer therapeutics and traded on the Mothers Market of the Tokyo Stock
Exchange (Code Number: 4591), today announced positive top-line results
from its SUSHI study, Phase 1/2a single ascending dose clinical study of
RBM-007, anti-FGF2 aptamer, in nine subjects with wet Age-Related
Macular Degeneration (wet AMD). SUSHI study achieved the primary
endpoint of safety and tolerability, and also demonstrated efficacy
trends in favor of RBM-007.
Subjects recruited for the SUSHI Study had wet AMD that was poorly
responsive to previous intravitreal anti-VEGF therapy. Through the
56-Day exit visit, excluding one uncompleted case in the last cohort,
single dose of RBM-007 demonstrated no dose-limiting toxicities, no
systemic or ocular serious adverse events. One subject in Cohort 3
showed anterior inflammation, which was resolved after one day of
topical prednisolone treatment. Rescue treatment with anti-VEGF therapy
was available for those subjects who met criteria.
Secondary outcomes at the primary study endpoint of 28 days showed
evidence of bioactivity of RBM-007. Seven out of nine subjects responded
to RBM-007, in terms of any vision gain in Best- Corrected Visual Acuity
(BCVA) or ≥50 µm improvement in Central Retinal Thickness on optical
coherence tomography (OCT) as reported in case report forms. Vision
improved at Day 28 in 2 subjects in Cohort 1, 2 subjects in Cohort 2 and
1 subject in Cohort 3. OCT improvement ≥50 µm at Day 28 was noted in 1
subject in Cohort 2 and all Cohort 3 subjects.
Overall, a single
intravitreal injection of RBM-007 in the study eye was well-tolerated
and indicated bioactivity in a majority of these wet AMD subjects, who
had been poorly responsive to prior anti-VEGF therapy.
Additional data analyses of SUSHI study are on-going and will be
presented at future medical meetings. Planning for the next multi-dose
Phase 2 clinical trial is underway and enrollment is expected to begin
in 3Q of FY2019.
“We are very encouraged by the results of SUSHI study. This was designed
as a first-in-human, single-dose safety study and has exceeded our
expectations from the standpoint of bioactivity. We will promote the
clinical development of RBM-007 to provide wet AMD patients with this
new solution as quickly as possible.” said Yoshikazu Nakamura, Ph.D.,
CEO and president of RIBOMIC Inc.
“SUSHI study has demonstrated that single dose of intravitreal RBM-007
up to 2 mg dose is well-tolerated in subjects with wet AMD. We are
pleased to demonstrate evidence of clinical efficacy in several subjects
as measured by BCVA and OCT thickness suggesting FGF2 is an important
target in the pathogenesis of wet AMD” said Yusuf Ali, Ph.D., CEO of
RIBOMIC USA Inc.
“The SUSHI study results demonstrate the ocular safety of intravitreal
RBM-007, and the improvements seen in eyes with chronic exudation hold
promise for a new therapeutic target in wet AMD” said Robert Bhisitkul,
MD. Ph.D., Professor at University of California San Francisco, and an
executive scientific advisor of RIBOMIC Inc.
About RBM-007 and development background
RBM-007 is a novel oligonucleotide-based aptamer with potent anti-FGF2
(fibroblast growth factor 2) activity. Currently approved therapies for
wet AMD, intravitreal injections of anti-VEGF drugs, have shown dramatic
visual benefits for wet AMD patients. However, a significant portion of
wet AMD patients exhibit incomplete response to therapy, and over the
extended management course can lose vision, with the formation of
submacular fibrosis as one risk factor. RIBOMIC investigated a novel
therapy for wet AMD targeting fibroblast growth factor 2 (FGF2), which
is implicated in not only angiogenesis but also fibrosis in several
diseases, and created RBM-007, a novel oligonucleotide-based aptamer
with potent anti-FGF2 activity. RBM-007 is chemically synthesized, and
pharmacokinetic studies of RBM-007 in the rabbit vitreous revealed high
and relatively long lasting profiles, which are superior to the other
approved anti-VEGF drugs. The dual action of RBM-007 (anti-angiogenic
and anti-scarring) holds promise as an additive or alternative therapy
to anti-VEGF treatments for wet AMD.
About SUSHI study
The Phase 1/2a Safety and ocUlar
tolerability of a Single intravitreal (IVT)
injection of RBM-007 in subjects witH exudatIve
age-related macular degeneration (SUSHI) study is an open-label, dose
escalation study with 9 subjects who had previously received ≥3
anti-VEGF treatments without resolution of wet AMD. Study eyes received
a single intravitreal injection of RBM-007 in 3 sequential dose cohorts
(3 subjects/cohort): 0.2 mg (Cohort 1), 1.0 mg (Cohort 2) and 2.0 mg
(Cohort 3). The primary study endpoint was at Day 28, with follow-up
through Day 56. Study visits included ETDRS best-corrected visual acuity
(BCVA), complete ophthalmologic exam, fluorescein angiography, spectral
domain-OCT, OCT-angiography and PK/PD RBM-007 plasma levels. This is the
first clinical study of RBM-007. Currently no other FGF2 inhibitors are
reported to be in the clinical stage.
See ClinicalTrials.gov for
more information.
https://clinicaltrials.gov/ct2/show/NCT03633084
About wet Age-related Macular Degeneration
Wet (exudative) age-related macular degeneration, is the leading cause
of blindness in the United States and Europe. It is caused by the
formation of abnormal and leaky new blood vessels under the retina,
termed choroidal neovascularization. The leakage of fluid from the
vessels causes retinal thickening and retinal degeneration including
fibrotic scar formation, and leads to severe and rapid loss of vision.
While retinal thickening is not the only factor that leads to decreased
vision in patients with wet AMD, it is thought to be a contributing
factor. In this regard, reduction of retinal thickness is widely used in
evaluating efficacy of wet AMD treatment.
ABOUT RIBOMIC
RIBOMIC is a bio-venture company centered on drug discovery. The company
is engaged in the field of aptamer therapeutics, which is one type of
nucleic acid medicine, a field with much potential for the development
of next-generation drugs. The RiboART system, the company’s core drug
discovery platform, can be used for the discovery of many types of
aptamer drugs. RIBOMIC is dedicated to the discovery and development of
drugs that target the broad field of unmet medical needs, which
encompasses eye disorders, pain and many other problems.
See
RIBOMIC website for more information.
https://www.ribomic.com/eng/index.php
Forward-Looking Statements
This announcement contains forward-looking statements relating to
current plans, estimates, strategies, belief and the future performance
of RIBOMIC. These statements are based on RIBOMIC’s current expectations
in light of the information and assumptions currently available so that
RIBOMIC does not promise the realization and these expectations may
differ materially from those discussed in the forward-looking
statements. These factors include, but not limited to, i) changes in
general economic conditions and in laws and regulations, relating to
pharmaceutical markets, ii) currency exchange rate fluctuations, iii)
claims and concerns on the product safety and efficacy, iv) completion
and discontinuation of clinical trials, v) infringement of RIBOMIC’s
intellectual property rights by third parties.
Information on
pharmaceutical products (including products currently in development),
which is included in this press release is not intended to constitute an
advertisement or medical advice.
“RIBOMIC,” “RiboART system” and the RIBOMIC logo are registered
trademarks or trademarks of RIBOMIC Inc. in various jurisdictions.
Contacts
RIBOMIC, Inc.
Shoji Yonebayashi
ir.inquiry@ribomic.com